Description
What is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide based on the native GIP sequence and engineered for dual agonism at the GIP and GLP-1 receptors. It incorporates non-coded aminoisobutyric-acid residues and a C20 fatty-diacid chain that extends its molecular half-life through albumin binding. As a research compound it is a widely referenced model for combined incretin-receptor pharmacology and energy-balance mechanisms.
How Tirzepatide works (research context)
In laboratory models tirzepatide simultaneously activates the GIP and GLP-1 receptors, two class-B GPCRs signaling predominantly via cAMP and downstream insulinotropic and appetite-regulatory pathways. Its GIP backbone with Aib substitutions resists enzymatic degradation, while the lysine-linked C20 fatty-diacid drives high albumin binding to prolong exposure. The dual engagement is studied for effects that differ from single GLP-1 agonists.
Research applications
- In-vitro characterization of dual GIP/GLP-1 receptor signaling
- Pre-clinical metabolic and glucose-homeostasis research
- Comparative studies versus single GLP-1 and triple agonists
- Receptor-binding, cAMP, and beta-arrestin assay development
Key facts
- Development code LY3298176; synthetic 39-amino-acid peptide based on GIP
- Contains Aib at positions 2 and 13 with a C-terminal amide
- Lys20-linked C20 fatty-diacid yields a multi-day half-life in models
- Supplied lyophilized; reconstitute with bacteriostatic water for in-vitro use
Product specifications
- Class: Dual GIP/GLP-1 receptor agonist
- Also known as: LY3298176
- Form: Lyophilized powder vial
- Purity: ≥ 99% (HPLC verified)
- Testing: Independent third-party HPLC + mass spectrometry
- Documentation: Certificate of analysis per batch
- Storage: Store lyophilized at -20C; reconstituted solution refrigerated at 2-8C, protected from light.
For laboratory research use only. Not for human or veterinary use, consumption, diagnostic, or therapeutic purposes.
R. Delgado (verified owner) –
Good quality powder, clear labeling and lot number. Packaging could be a touch sturdier but everything arrived intact.
Dr. Aaron Webb (verified owner) –
Tirzepatide reconstituted crystal clear. Mass spec matched the 39-residue sequence and the Aib substitutions checked out. Reliable reference standard for dual-agonist work.
Sasha Kim (verified owner) –
99.3% by HPLC on the COA and it held up against our own purity check. Consistent material order to order.
Dr. Nadia Cho (verified owner) –
Used the 30mg in GIP/GLP-1 cAMP assays — clean dose-response, low variance. The fatty-diacid material behaved exactly as expected.
Felix Brandt –
Fast, discreet shipping and the certificate of analysis was thorough. No complaints on the LY3298176.